Randomised, Double-Blind, Placebo-Controlled Trial of Ivabradine in Patients with Acute Coronary Syndrome: Effects of the I f Current Inhibitor Ivabradine on Reduction of Inflammation Markers in Patients with Acute Coronary Syndrome—RIVIERA Trial Study Design and Rationale-Reference-Cited by-同舟云学术

Randomised, Double-Blind, Placebo-Controlled Trial of Ivabradine in Patients with Acute Coronary Syndrome: Effects of the I f Current Inhibitor Ivabradine on Reduction of Inflammation Markers in Patients with Acute Coronary Syndrome—RIVIERA Trial Study Design and Rationale

Published:2009-02-20 Issue:3 Volume:23 Page:243-247
ISSN:0920-3206
Container-title:Cardiovascular Drugs and Therapy
language:en
Short-container-title:Cardiovasc Drugs Ther

Author:

Dominguez-Rodriguez Alberto,Fard Sima Samimi,Abreu-Gonzalez Pedro,Bosa-Ojeda Francisco,Consuegra-Sanchez Luciano,Jiménez-Sosa Alejandro,Grande Alejandro Sánchez,Kaski Juan Carlos

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10557-009-6164-9.pdf

Reference19 articles.

1. Ross T. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801–9.

2. Morrow DR, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol. 1998;31:1460–5.

3. Phillips AN, Neaton JD, Cook DG, et al. Leukocyte count and risk of major coronary heart disease events. Am J Epidemiol. 1992;136:59–70.

4. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–9.

5. Huikuri HV, Malkikallio TH, Airaksinen KEJ, et al. Power-law relationship of heart rate variability as a predictor of mortality in the elderly. Circulation 1998;97:2031–6.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized Approaches to Cardiovascular Disease: Insights into FDA-Approved Interventions and Clinical Pharmacogenetics;Current Pharmaceutical Design;2024-06

2. Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System in L-NAME-Induced Hypertension;International Journal of Molecular Sciences;2018-10-03

3. Ticagrelor vs. clopidogrel in non-ST-elevation acute coronary syndromes;Herz;2015-11-02

4. Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4;Journal of Molecular and Cellular Cardiology;2015-08

5. The effect of ivabradine on long term prevention of major adverse cardiac events in acute coronary syndrome using high-sensitivity C-reactive protein level;The Egyptian Journal of Critical Care Medicine;2015-08